Tofacitinib is under clinical development by Biora Therapeutics and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I drugs for Ulcerative Colitis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tofacitinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tofacitinib overview
Tofacitinib (PGN-600) is under development for the treatment of ulcerative colitis. The drug candidate is administered through oral route in the form of liquid. It acts by targeting JAK kinase. It is a drug-device combination being developed based on NaviCap Drug Delivery System (DDS) platform.
Biora Therapeutics overview
Biora Therapeutics, formerly Progenity Inc, is a biotechnology company. It develops oral biotherapeutics to replace injection with needle-free. The company’s pipeline products portfolio includes PGN-600 and PGN-001 liquid formulations delivered with the drug delivery system for the treatment of ulcerative colitis; liquid formulation of anti-TNF-alpha monoclonal antibody delivered with the oral biotherapeutics delivery system for the treatment of autoimmune conditions; and liquid formulation. It develops smart capsule platforms recoverable sampling systems and PIL Dx for GI sampling and diagnostics. The company delivers therapeutics to the site of diseases in the gastrointestinal tract, ulcerative colitis, and inflammatory bowel disease. Biora Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of Tofacitinib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
